- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Annexin Pharmaceuticals AB: First patient treated with vanexin following anti-VEGF injection in the NEXUS study | 173 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces that the first patient in the expanded patient cohort of the NEXUS study has now been treated according to the new study design. The patient, diagnosed with retinal... ► Artikel lesen | |
| 21.08. | Annexin Pharmaceuticals AB: Annexin advances the NEXUS study to include patients who received an anti-VEGF injection | 207 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces a next patient cohort in the NEXUS study. The company continues to study the effects of the drug candidate vanexin (formerly ANXV) in patients with retinal vein... ► Artikel lesen | |
| 20.08. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV | 249 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for the company's drug candidate ANXV.... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.07. | Annexin Pharmaceuticals AB: Annexin updates on nine patients treated in NEXUS study | 226 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the patient recruitment status in the NEXUS study. As of today, six patients with retinal vein occlusion (RVO) and three patients with diabetic retinopathy... ► Artikel lesen | |
| 03.07. | Annexin Pharmaceuticals AB: Annexin's rights issue 98 percent subscribed | 296 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 23.06. | Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO | 289 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been associated with limiting safety or tolerability... ► Artikel lesen | |
| 15.06. | Annexin Pharmaceuticals AB: The subscription period in Annexin Pharmaceuticals' rights issue begins today | 264 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 12.06. | Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB | 364 | GlobeNewswire | With effect from June 15, 2026, the subscription rights in Annexin Pharmaceuticals AB will be traded on First North Growth Market. Trading will continue up until and including June 29, 2026.
... ► Artikel lesen | |
| 10.06. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue | 235 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 09.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | 968 | Xetra Newsboard | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| 03.06. | Annexin Pharmaceuticals AB: Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million | 273 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 21.05. | Annexin Pharmaceuticals AB: Annexin investigates a three-day ANXV treatment regimen in patients with RVO | 289 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces a shortening of the ANXV treatment regimen from five to three days at the same dose level. A three-day treatment is expected to strengthen the commercial value... ► Artikel lesen | |
| 11.05. | Annexin Pharmaceuticals AB: Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study | 293 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the company has received an approval for a clinical trial with the drug candidate ANXV by the German Medicines Agency Bundesinstitut für Arzneimittel... ► Artikel lesen | |
| 22.04. | Annexin Pharmaceuticals AB: Annexin accelerates patient recruitment - five patients treated | 342 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO)... ► Artikel lesen | |
| 13.04. | Annexin Pharmaceuticals AB: Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026 | 281 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20 million... ► Artikel lesen | |
| 04.02. | Annexin Pharmaceuticals AB: Favourable findings in Annexin's ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion | 715 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion... ► Artikel lesen | |
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 351 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna zeigt, wie schwierig der Sprung von der Studie zum Geschäftsmodell ist - ein Biotech aus Australien macht es vor | ||
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| ABSCI | 10,165 | +0,05 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen ANNEXIN PHARMACEUTICALS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,772 Euro und damit -0,26 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.